Clinical trials in Rome – page 58

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Rome at a glance

2 209

clinical trials

Research sites15

Quick filters

2 209 trials in Rome

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Study on Valproic Acid, Simvastatin, and Gemcitabine for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo

Study on Valproic Acid, Simvastatin, and Gemcitabine for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Recruiting

Registered drug

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Acute respiratory distress syndrome

Recruiting

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Human Plasma Gelsolin, Recombinant
Sponsor:Bioaegis Therapeutics Inc.

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Janssen Cilag International

Contact Research Centre

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Ponatinib
Sponsor:Incyte Biosciences International S.a.r.l.

Contact Research Centre

Atypical haemolytic uraemic syndrome

Recruiting

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

Pulmonary function assessment
Disease exacerbation prevention
RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

Targeted molecular therapies
Combination treatment approaches
Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

Early disease intervention
Stroke treatment optimization
Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

Immune system modulation
Novel biological therapies
Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to Italy All countries